Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.58 |
| ▸ | CALML3 | P27482 | 7/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SDHA | P31040 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897915 | 0.90 | MAOA (0.56) | MAOACALML3CYP3A4CYP2C19MAOB | |
| SCHEMBL2890865 | 0.85 | MAOA (0.61) | MAOACALML3CYP3A4CYP2C19MAOB | |
| SCHEMBL2897058 | 0.83 | MAOA (0.68) | MAOACALML3CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6609999 | 0.83 | MAOA (0.61) | MAOACALML3CYP3A4CYP2C19MAOB | |
| SCHEMBL5815643 | 0.81 | MAOA (0.66) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL18770298 | 0.79 | MAOA (0.57) | MAOACALML3CYP3A4CYP2C19MAOB | |
| SCHEMBL20528026 | 0.79 | MAOA (0.57) | MAOACALML3CYP3A4CYP2C19MAOB | |
| SCHEMBL20528017 | 0.79 | MAOA (0.57) | MAOACALML3CYP3A4CYP2C19MAOB | |
| SCHEMBL2891065 | 0.77 | MAOA (0.55) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL21244315 | 0.77 | MAOA (0.55) | MAOACALML3CYP3A4CYP2C19MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-11 | — | — | US | disclosed |
| EP-1799677-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | Ranbaxy Laboratories Limited (IN) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006038100-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | OXA1L, PDK4, MLYCD | MAOA 1717/4885CALML3 3047/4885CYP3A4 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.